City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Przemyslaw Twardowski, MD  
Search results:  6  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-6 Trials Jump to page:

COH Protocol Number: 13439 ClinicalTrials.gov Number: NCT01524991

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Institutional

Title:  Phase II Trial of Gemcitabine, Cisplatin, plus Ipilimumab as First-line Treatment for Patients with Metastatic Urothelial Carcinoma

COH Protocol Number: 13365 ClinicalTrials.gov Number: NCT01967862

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Institutional

Title:  F18 NaF PET/CT and Whole Body and axial MRI for the Detection of Metastases in Patients with Biochemical Recurrence of Prostate Cancer

COH Protocol Number: 13178 ClinicalTrials.gov Number: NCT01809691

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Cooperative Group

Title:  SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

COH Protocol Number: 13120 ClinicalTrials.gov Number: NCT01946204

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Industrial

Title:  A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

COH Protocol Number: 12367 ClinicalTrials.gov Number: NCT01807065

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Institutional

Title:  Randomized Phase II Trial of Sipuleucel T Immunotherapy Preceded by Sensitizing Radiation Therapy and Sipuleucel-T Alone in Patients with Castrate Resistant Metastatic Prostate Cancer

COH Protocol Number: 06049 ClinicalTrials.gov Number: NCT00365157

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-75, NCI #7435: A Phase I/II Study of E7389 Halichondrin B Analog (NSC 707389; IND #64395) in Metastatic Urothelial Tract Cancer and Renal Insufficiency

 
Results per page: 25 50 100 All 1-6 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.